CKPT

Checkpoint Therapeutics (CKPT)

About Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Details

Daily high

$3.04

Daily low

$2.68

Price at open

$3.00

52 Week High

$4.50

52 Week Low

$1.38

Market cap

135.3M

Dividend yield

0.00%

Volume

1.8M

Avg. volume

979,120

P/E ratio

-1.92

Checkpoint Therapeutics News